UniQure Moves Toward Accelerated Approval Path For AMT-130 After FDA Signals Support; Stock Up

uniQure N.V. (QURE) said the feedback came during a recent Type B meeting with the agency, where regulators confirmed that the three-year analysis from its Phase I/II study would be acceptable as the primary foundation for a BLA submission for AMT-130, its gene therapy for Huntington's disease.